Core Insights - Myriad Genetics has secured a five-year senior secured term loan credit facility of up to $200 million from OrbiMed, which includes $125 million of funded capital and an option to borrow an additional $75 million until June 30, 2027 [1][2] - The facility matures on July 31, 2030, and has an interest rate based on the one-month secured overnight financing rate (SOFR) plus 6.50%, with a SOFR floor of 2.50% [1] - The new credit facility replaces Myriad's previous asset-based lending (ABL) facility and is secured by substantially all the assets of Myriad Genetics and its subsidiaries [2] Company Overview - Myriad Genetics is a leader in molecular diagnostic testing and precision medicine, focusing on advancing health and well-being through molecular tests that assess disease risk and guide treatment decisions [3] - The company aims to improve patient care and reduce healthcare costs through its diagnostic tests [3] Partner Overview - OrbiMed is a prominent healthcare investment firm with over $17 billion in assets under management, investing globally across the healthcare industry [4] - The firm provides tailored financing solutions and extensive resources to support the growth of healthcare companies [4]